Articles by William Looney - Pharmaceutical Executive


Articles by William Looney

Taking Stock: Notes on the Industry Audit

Oct 1, 2013

Our October issue highlights a latent threat to Big Pharma: the behavioral mindset that may be best characterized as "ageing in place."

Trying to Control Pharma Costs?

Sep 1, 2013

A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, lifealtering diseases.

Crunch TIme for Emerging Markets

Sep 1, 2013

Normal service will be resumed as soon as possible.

What Makes an Emerging Pharma Leader

Aug 14, 2013

Editorial Director William Looney discusses the five essential characteristics exhibited by the more than 200 men and women selected by Pharmaceutical Executive as Emerging Pharma Leaders

Breaching the Great Wall

Aug 1, 2013

With a revision of China's basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation.

One Company—One Moment

Aug 1, 2013

The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China—ironically, the country touted as guarantor of our industry's future.

Succinctly Shire: CEO Flemming Ornskov

Aug 1, 2013

Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate.

Talent, Terror, and the Turnaround

Jul 1, 2013

Our lead feature this month on 15 new Emerging Pharma Leaders is a window into what makes our publication unique. In 2007, Pharm Exec began a systematic annual search to identify and highlight those men—and women—that in our purely editorial view had real prospects for a future key to the "c suite." Two of our early choices—Sanofi's Chris Viehbacher and Heather Bresch of Mylan—have made it to the very top, as CEO.

Recognizing the Best

Jun 1, 2013

Getting patients to take their medicine on spec and on time is the challenge that never goes away—it's the deadweight baggage accompanying every industry innovation since the arrival of aspirin a century ago.


Click here